328 124I GC33 Positron Emission Tomography (PET), Imaging Biomarker of Glypican-3 in Hepatocellular CarcinomaAbou-Alfa, G.K.European Journal of Cancer2012DOI 10.1016/s0959-8049(12)72126-3
Japanese Phase I Study of GC33, a Humanized Antibody Against Glypican-3 for Advanced Hepatocellular CarcinomaIkeda, MasafumiJohn Wiley and Sons2014DOI 10.1111/cas.12368
318 Effects of Radiologic Tumor Response of Anti-Glypican-3 GC33 and Multi Tyrosine Kinases Inhibitor Sorafenib in Hepatocellular CarcinomaAbou-Alfa, G.K.Elsevier Science2012DOI 10.1016/s0959-8049(12)72116-0
&Agr;-Fetoprotein (Afp) Response By Gc33 Correlates to Progression Free Survival (Pfs) in Patients with Advanced Hepatocellular Carcinoma (Hcc)Jin, Y.Oxford University Press2014DOI 10.1093/annonc/mdu326.65
First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular CarcinomaZhu, A. X.American Association for Cancer Research2013DOI 10.1158/1078-0432.ccr-12-2616
Histopathological Analyses of the Antitumor Activity of Anti-glypican-3 Antibody (GC33) in Human Liver Cancer Xenograft Models: The Essential Role of MacrophagesTakai, HirotakeLandes Bioscience2009DOI 10.4161/cbt.8.10.8149